Cancer programs seek to remove barriers to screenings.
Cancer deaths are expected to increase over the next decade due to screening deficits caused by the COVID-19 pandemic, according to new research.
Around the nation, 748 accredited cancer programs reported decreases in screenings for colorectal (80.6%), cervical (69%), breast (55.3%) and lung cancer (44.6%), according to a study initiated by the American College of Surgeons Cancer Programs and the American Cancer Society.
The results were announced by Wiley and published in Cancer, the journal of the American Cancer Society.
“From the perspective of people’s health, we are hopeful that this collaborative effort between the American College of Surgeons Cancer Programs and the American Cancer Society may have saved many patients from unnecessary suffering and death from cancer,” co-author Heidi Nelson, MD, FACS, said in a news release.
The study period took place from April 2021 through June 2021.
Using the results, the participating cancer programs initiated 814 quality improvement projects to address various barriers to screening, and are assessing the effects of those interventions.
If all participating facilities reach their target goals, the estimated numbers of potential additional monthly screening tests are:
“From the perspective of what this means about our programs, we now know that we can turn to our accredited programs in times of crisis to help address large-scale cancer problems,” said Nelson, who is medical director of cancer programs at the American College of Surgeons. “Knowing how enthusiastic these accredited programs are for working collaboratively on national level problems, we expect to release one or two quality improvement projects each year going forward.”
Researchers did not see geographic differences based on the locations of cancer programs across the United States.
The researchers said the study was timely because the American Cancer Society's National Consortium for Cancer Screening and Care recently announced nine consensus recommendations to accelerate recovery from the pandemic and improve the nation's ability to provide quality cancer screening and care for all.
This article was originally published on Medical Economics®.
Shift towards neoadjuvant chemotherapy found in ovarian cancer treatment
October 21st 2024A recent study shows a significant decrease in primary cytoreductive surgery utilization for advanced ovarian cancer, as neoadjuvant chemotherapy followed by interval cytoreductive surgery gains acceptance for its noninferior survival outcomes and reduced postoperative morbidity.
Read More
Family history criteria used to predict breast cancer genetic risk variants
September 26th 2024In a recent study, patients with a positive response to the Seven-Question Family History Questionnaire were more likely to present with a pathogenic or likely pathogenic variant in the BRCA1 and BRCA2 genes.
Read More